Novo Nordisk
Company ● Covered in 1 story + Follow ✴ AI Graph
This profile is built automatically from TLDRocket coverage.
Signals
1 story (new)
Media momentum
As of 21 Sep 2026 · Visible stories in the last 30 days, compared with the 30 days before.
1 source
Source diversity
As of 21 Sep 2026 · Distinct publications behind this entity's visible coverage.
—
Release activity
As of 21 Sep 2026 · Model, product and open-source release events in the last 90 days whose coverage involves this entity.
—
Funding signals
As of 21 Sep 2026 · Funding and acquisition events in the last 90 days whose coverage involves this entity.
Sep 2026
Coverage span
As of 21 Sep 2026 · First to most recent month of TLDRocket coverage of this entity.
Management
updated 21 Sep 2026- Anonymous President & CEO
- Tania Sabroe Executive Vice President, People, Organisation & Corporate Affairs
- Yiannis Mallis Senior Vice President Portfolio Strategy & Access
- Jamey Millar Executive Vice President, US Operations
- Hong Chow Executive Vice President, Product & Portfolio Strategy
- Anja Jørgensen Vice President - Head of the Corporate Ombudsman Function
- Martin Holst Lange Executive Vice President of R&D & Chief Scientific Officer
- Alan Moses Senior Vice President And Global Chief Medical Officer
- Doug Langa Executive Vice President & Senior VP, Head of North America Operations and President of NNI
- Karsten Munk Knudsen Executive Vice President, Chief Financial Officer
- Steven Benz Corporate Vice President, General Counsel, Novo Nordisk Inc., US Operations
- Kasper Bødker Mejlvang Executive Vice President, CMC & Product Supply
+ 18 more tracked
Latest developments
September 2026
Relationships
Products & technology
- Cellular Intelligence deploys this company · 1 source